Načítá se...

Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report

The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). However, a number of skin manifestations have been found in patients receiving erlotinib therapy. Leukocytoclastic vasculitis is a rare side-eff...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: SU, BO-AN, SHEN, WAN-LIN, CHANG, SHENG-TSUNG, FENG, LI-YIA, WU, CHIA-JUNG, FENG, YIN-HSUN
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3392574/
https://ncbi.nlm.nih.gov/pubmed/22783433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2012.647
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!